BioRay Pharmaceutical Co. has commenced the Phase I clinical trial for BRY812, an innovative antibody-drug conjugate (ADC) targeting LIV-1, a zinc transporter associated with cell growth in advanced malignancies. This trial is being conducted at Sun Yat-sen Memorial Hospital of Sun Yat-sen University, under the guidance of Academician Song Erwei and Professor Yao Herui.

LIV-1, also known as SLC39A6 or ZIP6, plays a vital role in the metabolism of intracellular zinc ions. BRY812, utilizing the exclusive CysLink™ technology, is the first LIV-1 ADC in China and the second globally to enter clinical trials. In preclinical studies, this novel ADC demonstrated significant inhibition of tumor growth, surpassing similar drugs in anti-tumor activity and stability.

The chemical conjugation technology platform utilized in BRY812 ensures superior stability in circulation, efficient payload delivery to tumors, and reduced toxin excretion. This results in an enhanced safety profile and an expanded therapeutic window compared to its counterparts. Moreover, BRY812 has the capability to induce immunogenic cell death (ICD) and enhance the effectiveness of immunotherapies such as anti-PD-(L)1.

BioRay, emphasized the potential of BRY812 to address various advanced malignancies, providing a wider range of treatment options for patients and establishing a significant market presence in the competitive ADC landscape.

 

Source: prnewswire.com

Report Abuse